Latest Market Entry News

Page 19 of 38
PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.
Ada Torres
Ada Torres
29 Aug 2025
Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.
Ada Torres
Ada Torres
29 Aug 2025
PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.
Victor Sage
Victor Sage
29 Aug 2025
PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Nuchev Limited reported a strong FY25 with revenue doubling to $22.9 million, driven by growth in Oli6® Nutritionals and the integration of bWellness Practitioner channel. Adjusted EBITDA loss narrowed significantly amid improved margins and cost control.
Victor Sage
Victor Sage
28 Aug 2025
EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.
Ada Torres
Ada Torres
28 Aug 2025
BetMakers Technology Group has completed a major transformation in FY25, delivering positive adjusted EBITDA and strong operating cash flow while expanding its global footprint with a strategic US acquisition.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Shriro Holdings reported a 13.6% revenue decline to $103.3 million in FY25 but delivered a 5.5% rise in EBITDA and an 8.7% increase in net profit after tax. The company completed a $15 million share buy-back and deferred its final dividend as it explores alternative capital uses.
Victor Sage
Victor Sage
27 Aug 2025
Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.
Ada Torres
Ada Torres
27 Aug 2025
Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.
Ada Torres
Ada Torres
26 Aug 2025
CVC Limited reports a stable FY2025 profit alongside a robust landbank poised for significant value uplift, targeting a net tangible asset per share of $5.75 through strategic rezoning and development.
Eva Park
Eva Park
26 Aug 2025